Proton pump inhibition for secondary hemochromatosis in hereditary anemia, a phase III placebo-controlled randomized cross-over clinical trial.
<|begin_of_text|><|start_header_id|>system<|end_header_id|> You are a research archivist expert in dataset metadata. Answer the question truthfully.  <|eot_id|><|start_header_id|>user<|end_header_id|> Here is the Description of a dataset. Description:'Iron overload is a severe general complication of hereditary anemias. Treatment with iron chelators is hampered by important side-effects, high costs and the lack of availability in many countries with high prevalence of hereditary anemias.Objective: to investigate the safety and efficacy of esomeprazole in treatment of iron overload in patients with non-transfusion-dependent hereditary anemias.Design: phase III randomized placebo-controlled cross-over trial.Setting: enrollment from March 2018 through April 2019 in five centers of expertise in the Netherlands.Participants: 30 adult patients with mild-to-moderate iron overload were enrolled (non-transfusion-dependent thalassemia (N=13), pyruvate kinase deficiency (N=8), congenital sideroblastic anemia (N=3), congenital dyserythropoietic anemia (N=3), sickle cell disease (N=2), and he' . Please return only a json list of at most 3 Keywords corresponding to the Description:.<|eot_id|><|start_header_id|>assistant<|end_header_id|> {"Answer" : ["Hereditary anemia","Iron overload","Red cells"]} <|eot_id|>
 Here is the Description of a dataset. Description:'Iron overload is a severe general complication of hereditary anemias. Treatment with iron chelators is hampered by important side-effects, high costs and the lack of availability in many countries with high prevalence of hereditary anemias.Objective: to investigate the safety and efficacy of esomeprazole in treatment of iron overload in patients with non-transfusion-dependent hereditary anemias.Design: phase III randomized placebo-controlled cross-over trial.Setting: enrollment from March 2018 through April 2019 in five centers of expertise in the Netherlands.Participants: 30 adult patients with mild-to-moderate iron overload were enrolled (non-transfusion-dependent thalassemia (N=13), pyruvate kinase deficiency (N=8), congenital sideroblastic anemia (N=3), congenital dyserythropoietic anemia (N=3), sickle cell disease (N=2), and he' . Please return only a json list of at most 3 Keywords corresponding to the Description:.
Iron overload is a severe general complication of hereditary anemias. Treatment with iron chelators is hampered by important side-effects, high costs and the lack of availability in many countries with high prevalence of hereditary anemias.Objective: to investigate the safety and efficacy of esomeprazole in treatment of iron overload in patients with non-transfusion-dependent hereditary anemias.Design: phase III randomized placebo-controlled cross-over trial.Setting: enrollment from March 2018 through April 2019 in five centers of expertise in the Netherlands.Participants: 30 adult patients with mild-to-moderate iron overload were enrolled (non-transfusion-dependent thalassemia (N=13), pyruvate kinase deficiency (N=8), congenital sideroblastic anemia (N=3), congenital dyserythropoietic anemia (N=3), sickle cell disease (N=2), and he
Hereditary anemia; Iron overload; Red cells